more_reports

VBL Therapeutics

VBLT:NASDAQ

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. VBL's lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors.

streetwise book logo Streetwise Company Fact Sheet

2024/7/13 5:09:51

(VBLT:NASDAQ)